Tropical malaria is one of the most dangerous infectious diseases in tropical and subtropical areas. Although the toll is 300-500 million cases and 2-3 million deaths per year, an effective malaria vaccine has not yet been developed. SE36 malaria vaccine is one of the promising candidates and clinical trial has been proceeded in Uganda. In this research, we develop a next generation SE36 malaria vaccine with an augmented immunogenicity by multiplying the protective epitopes in the antigen molecule and by addition of TLR9 ligand adjuvant that activates innate immunity. We will also identify a counterpart of SE36 antigen in tertian malaria and develop a tertian malaria vaccine.
When modification of SE36 vaccine by additional protective epitopes and TLR9 ligand adjuvant provoke higher immunogenicity, the vaccine will be useful for not only travelers and transients from non-endemic area but also inexpensive for the residents in endemic area. The tertian malaria vaccine will also be a preventive measure for two billion residents in endemic areas all over the world.
